Why it matters: White House officials had warned that initial shipments of the Johnson & Johnson vaccine would be limited due to manufacturing issues, despite the company announcing it would fulfill its agreement to supply the US with 100 million doses by the end of June.
“We are confident that we will ship 100 million single-dose vaccines to the US in the first half of 2021 and we continue to work with the US government to explore all options to expedite delivery,” Nettles said.
Overall, the vaccine is 66 percent effective against the virus, but showed only 57 percent effectiveness in a study in South Africa in which a problematic strain, B.1.315, became widespread. This strain has been reported in 10 US states.
What’s next: The House panel will also hear from executives from Pfizer, Moderna, AstraZeneca and Novavax how the major vaccine manufacturers are ramping up production to meet the country’s vaccine needs.
Pfizer and Moderna each pledged 300 million doses this year.